Robert W. Baird Raises Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $50.00

Mirum Pharmaceuticals (NASDAQ:MIRM - Free Report) had its price objective increased by Robert W. Baird from $44.00 to $50.00 in a research note published on Wednesday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Other analysts have also issued research reports about the company. Evercore ISI upped their target price on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an "outperform" rating in a report on Thursday, August 8th. Cantor Fitzgerald raised their price objective on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, August 8th. HC Wainwright reiterated a "buy" rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Friday, October 11th. Finally, Leerink Partners raised their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. Ten analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $57.73.

Mirum Pharmaceuticals Trading Up 4.7 %

Shares of NASDAQ:MIRM traded up $1.99 on Wednesday, hitting $44.27. 316,037 shares of the company's stock were exchanged, compared to its average volume of 556,821. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -21.81 and a beta of 1.16. Mirum Pharmaceuticals has a 12 month low of $23.14 and a 12 month high of $45.81. The company has a debt-to-equity ratio of 1.34, a current ratio of 3.28 and a quick ratio of 3.09. The business's 50 day simple moving average is $39.92 and its two-hundred day simple moving average is $35.73.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 40.98%. The company had revenue of $90.38 million during the quarter, compared to analysts' expectations of $81.99 million. During the same period in the previous year, the company earned ($0.57) EPS. The firm's quarterly revenue was up 89.4% on a year-over-year basis. Analysts anticipate that Mirum Pharmaceuticals will post -1.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently modified their holdings of MIRM. Quest Partners LLC increased its holdings in shares of Mirum Pharmaceuticals by 7,513.3% during the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company's stock valued at $39,000 after purchasing an additional 1,127 shares in the last quarter. Amalgamated Bank increased its holdings in Mirum Pharmaceuticals by 60.8% in the second quarter. Amalgamated Bank now owns 1,357 shares of the company's stock valued at $46,000 after buying an additional 513 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock worth $67,000 after acquiring an additional 318 shares during the period. ProShare Advisors LLC acquired a new position in shares of Mirum Pharmaceuticals in the second quarter worth about $213,000. Finally, Creative Planning purchased a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter worth about $249,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.